Keros Board approves $5M share buyback after milestone payment
Keros Therapeutics authorized a $5 million share repurchase program following a milestone payment from Takeda related to its elritercept pipeline. The biopharmaceutical company has flexibility to repurchase shares based on market conditions.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed